Clinical Trial Update: Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) [Phase 3]

View source ↗

Summary

Phase 3 trial update for Zevalin after R-CVP in previously untreated follicular lymphoma; study status terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Lymphoma Follicular

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Follicular Lymphoma, Lymphoma, Follicular | Phase 3 | Status: TERMINATED | Results posted: 2022-01-14